# US 2013/0251817 A1 · Cancer cell targeting using nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251817 A1
- Document ID: US20130251817A1
- Status: Published application
- Kind: A1
- Application number: 13/891,341
- Filed: 2013-05-10
- Published: 2013-09-26
- Earliest claimed: 2008-03-31
- Assignees: BIND Therapeutics, Inc.
- Applicants: Bind Therapeutics, Inc.
- Inventors: Stephen E. Zale; Mir Mukkaram Ali
- Web page: https://patentgrep.com/patent/US20130251817A1

## CPC

- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07C 275/16: being further substituted by carboxyl groups
- C07C 275/24: containing six-membered aromatic rings
- C08G 63/664: derived from hydroxy carboxylic acids
- C08G 63/6852: {derived from hydroxy carboxylic acids}
- C08G 63/6922: {derived from hydroxy carboxylic acids}
- Y10S 977/904: for medical, immunological, body treatment, or diagnosis
- Y10S 977/905: Specially adapted for travel through blood circulatory system
- Y10S 977/906: Drug delivery
- Y10S 977/911: Cancer cell destruction
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

## Claims

### Claim 1

A nanoparticle comprising:
(a) a chemotherapeutic agent;
(b) a diblock copolymer of poly(ethylene glycol) and polylactic acid; and
(c) a prostate specific membrane antigen ligand conjugated to a diblock copolymer of poly(ethylene glycol) and polylactic acid, wherein the prostate specific membrane antigen ligand has the structure

### Claim 2 (depends on 1)

The nanoparticle of claim 1 having a diameter in the range of 80 nm to 200 nm.

### Claim 3 (depends on 1)

The nanoparticle of claim 1 wherein the chemotherapeutic agent is paclitaxel, docetaxel, mitoxandrone, doxorubicin, gemcitabine, 5-fluorouracil, daunorubicin or 9-dihydrotaxol.

### Claim 4 (depends on 3)

The nanoparticle of claim 3 wherein the chemotherapeutic agent is paclitaxel, docetaxel or 9-dihydrotaxol.

### Claim 5 (depends on 4)

The nanoparticle of claim 4 wherein the chemotherapeutic agent is paclitaxel.

### Claim 6

A pharmaceutical composition comprising
(a) a plurality of nanoparticles, wherein each nanoparticle comprises:
a. a chemotherapeutic agent;
b. a diblock copolymer of poly(ethylene glycol) and polylactic acid; and
c. a prostate specific membrane antigen ligand conjugated to a diblock copolymer of poly(ethylene glycol) and polylactic acid, wherein the prostate specific membrane antigen ligand has the structure
and
(b) a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6 wherein the nanoparticles have a diameter of 80 nm to 200 nm.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6 wherein the chemotherapeutic agent is paclitaxel, docetaxel, mitoxandrone, doxorubicin, gemcitabine, 5-fluorouracil, daunorubicin or 9-dihydrotaxol.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6 wherein the chemotherapeutic agent is paclitaxel, docetaxel or 9-dihydrotaxol.

### Claim 10 (depends on 6)

The pharmaceutical composition of claim 6 wherein the chemotherapeutic agent is paclitaxel.

### Claim 11 (depends on 6)

A method of treating a solid tumor cancer in a subject in need thereof, comprising systemically administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 6.

### Claim 12 (depends on 11)

The method of claim 11 wherein the particles are administered by parenteral administration.

### Claim 13 (depends on 11)

The method of claim 11 wherein the parenteral administration is intravenous or subcutaneous administration.

### Claim 14 (depends on 11)

The method of claim 11 wherein the cancer is prostate cancer.

### Claim 15 (depends on 11)

The method of claim 11 wherein the cancer is non-small cell lung cancer.

### Claim 16 (depends on 11)

The method of claim 11 wherein the cancer is colorectal cancer or glioblastoma.

### Claim 17 (depends on 11)

The method of claim 11 wherein the nanoparticles have a diameter of 80 nm to 200 nm.

### Claim 18 (depends on 11)

The method of claim 11 wherein the chemotherapeutic agent is paclitaxel, docetaxel, mitoxandrone, doxorubicin, gemcitabine, 5-fluorouracil, daunorubicin or 9-dihydrotaxol.

### Claim 19 (depends on 11)

The method of claim 11 wherein the chemotherapeutic agent is paclitaxel, docetaxel or 9-dihydrotaxol.

### Claim 20 (depends on 11)

The method of claim 11 wherein the chemotherapeutic agent is paclitaxel.
